Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies

Posted:
7
November 2012

Cardiac Safety: Key issues and best practice for Thorough QT Studiesand Intensive Phase I QT Studies~ A specialist workshop sponsored by Richmond Pharmacology ~

As collaborating sponsors of the joint AMIFE IFAPP 16th International Conference on Pharmaceutical Medicine � ICPM 2012, Richmond Pharmacology welcomes attendees to join its specialist workshop on Day 2, 15 Nov exploring �Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies�.Co-chaired by the internationally acclaimed experts Beno�t Tyl, Georg Ferber and Jorg Taubel, the workshop will look at the biological background to the ICH E14 guidance. They will present the rationale of the thorough QT study and discuss the key elements of a state of the art design and analysis of such a study. The second half of the workshop will address the placement of the TQT study in clinical development and give an update on current CSRC discussions and on conditions under which regulators may be likely to waive a TQT study at present and in future.Attendees are encouraged to submit questions or current problems they may wish the panel to address during the roundtable discussions in advance to:info@richmondpharmacology.comView ICPM 2012 Scientific ProgramRegister for this conference

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more